File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial

TitlePostoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial
Authors
Issue Date1998
PublisherAmerican Medical Association. The Journal's web site is located at http://www.archsurg.com
Citation
Archives Of Surgery, 1998, v. 133 n. 2, p. 183-188 How to Cite?
AbstractObjective: To study the effect of adjuvant chemotherapy after curative hepatic resection in patients with hepatocellular carcinoma. Design: A randomized controlled thai. Setting: A tertiary referral center. Patients: During a 54-month period, 142 patients with hepatocellular carcinoma underwent hepatic resection at 1 institution. Sixty-six patients who survived the operation and had no demonstrable evidence of residual disease on ultrasonographic examination and hepatic angiographic testing at 1 month after surgery agreed to participate in the study. The median follow-up time was 28.3 months. Intervention: Thirty patients received a combination of intravenous epirubicin hydrochloride (8 doses of 40 mg/m 2 each at 6-week intervals) and transarterial chemotherapy using an emulsion of iodized oil and cisplatin (3 courses with a maximum dose of 20 mL each at 2-month intervals). Thirty-six patients had no adjuvant treatment. Main Outcome Measures: Recurrence rate and disease-free survival. Results: A total of 138 courses of intravenous epirubicin was given to the 30 patients. Sixty-one courses of transarterial chemotherapy were given to only 29 of the 30 patients assigned to the treatment group, because the hepatic artery in 1 patient was thrombosed. Six patients (20%) had chemotherapy-related complications with no mortality. Twenty-three of 30 patients in the treatment group and 17 of 36 patients in the control group had recurrences (P=.01). Patients who received adjuvant chemotherapy had a higher incidence of extrahepatic metastases (11 patients vs 5 patients; P=.03). The respective disease-free survival rates at 1, 2, and 3 years were 50%, 36%, and 18% for the treatment group and 69%, 53%, and 48% for the control group (P=.04). Conclusion: In a group of patients who underwent curative resection of hepatocellular carcinoma, postoperative adjuvant chemotherapy using the present regimen was associated with more frequent extrahepatic recurrences and a worse outcome.
Persistent Identifierhttp://hdl.handle.net/10722/49321
ISSN
2014 Impact Factor: 4.926
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, ECSen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2008-06-12T06:39:27Z-
dc.date.available2008-06-12T06:39:27Z-
dc.date.issued1998en_HK
dc.identifier.citationArchives Of Surgery, 1998, v. 133 n. 2, p. 183-188en_HK
dc.identifier.issn0004-0010en_HK
dc.identifier.urihttp://hdl.handle.net/10722/49321-
dc.description.abstractObjective: To study the effect of adjuvant chemotherapy after curative hepatic resection in patients with hepatocellular carcinoma. Design: A randomized controlled thai. Setting: A tertiary referral center. Patients: During a 54-month period, 142 patients with hepatocellular carcinoma underwent hepatic resection at 1 institution. Sixty-six patients who survived the operation and had no demonstrable evidence of residual disease on ultrasonographic examination and hepatic angiographic testing at 1 month after surgery agreed to participate in the study. The median follow-up time was 28.3 months. Intervention: Thirty patients received a combination of intravenous epirubicin hydrochloride (8 doses of 40 mg/m 2 each at 6-week intervals) and transarterial chemotherapy using an emulsion of iodized oil and cisplatin (3 courses with a maximum dose of 20 mL each at 2-month intervals). Thirty-six patients had no adjuvant treatment. Main Outcome Measures: Recurrence rate and disease-free survival. Results: A total of 138 courses of intravenous epirubicin was given to the 30 patients. Sixty-one courses of transarterial chemotherapy were given to only 29 of the 30 patients assigned to the treatment group, because the hepatic artery in 1 patient was thrombosed. Six patients (20%) had chemotherapy-related complications with no mortality. Twenty-three of 30 patients in the treatment group and 17 of 36 patients in the control group had recurrences (P=.01). Patients who received adjuvant chemotherapy had a higher incidence of extrahepatic metastases (11 patients vs 5 patients; P=.03). The respective disease-free survival rates at 1, 2, and 3 years were 50%, 36%, and 18% for the treatment group and 69%, 53%, and 48% for the control group (P=.04). Conclusion: In a group of patients who underwent curative resection of hepatocellular carcinoma, postoperative adjuvant chemotherapy using the present regimen was associated with more frequent extrahepatic recurrences and a worse outcome.en_HK
dc.format.extent418 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherAmerican Medical Association. The Journal's web site is located at http://www.archsurg.comen_HK
dc.relation.ispartofArchives of Surgeryen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAntineoplastic Agents - therapeutic useen_HK
dc.subject.meshCarcinoma, Hepatocellular - drug therapy - pathology - surgeryen_HK
dc.subject.meshLiver Neoplasms - drug therapy - pathology - surgeryen_HK
dc.subject.meshChemotherapy, Adjuvanten_HK
dc.subject.meshCisplatin - administration & dosageen_HK
dc.titlePostoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0004-0010&volume=133&issue=2&spage=183&epage=188&date=1998&atitle=Postoperative+adjuvant+chemotherapy+after+curative+resection+of+hepatocellular+carcinoma:+a+randomized+controlled+trialen_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1001/archsurg.133.2.183en_HK
dc.identifier.pmid9484732-
dc.identifier.scopuseid_2-s2.0-0031914335en_HK
dc.identifier.hkuros32005-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031914335&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume133en_HK
dc.identifier.issue2en_HK
dc.identifier.spage183en_HK
dc.identifier.epage188en_HK
dc.identifier.isiWOS:000072063200012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, ECS=36932159600en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLiu, CL=7409789712en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats